RT Journal Article
T1 Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
A1 Jara-Palomares, Luis
A1 Solier-Lopez, Aurora
A1 Elias-Hernandez, Teresa
A1 Asensio-Cruz, Maribel
A1 Blasco-Esquivias, Isabel
A1 Marin-Barrera, Lucia
A1 de la Borbolla-Artacho, Maria Rodriguez
A1 Praena-Fernandez, Juan Manuel
A1 Montero-Romero, Emilio
A1 Navarro-Herrero, Silvia
A1 Serrano-Gotarredona, Maria Pilar
A1 Sánchez-Díaz, José María
A1 Palacios, Carlos
A1 Otero, Remedios
K1 Cancer
K1 Low-molecular-weight heparin
K1 Pulmonary embolism
K1 Tinzaparin
K1 Venous thromboembolism
AB The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1-6 and 7-12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p=0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p=0.02). The incidence of VTE recurrence at months 1-6 and 7-12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Treatment with tinzaparin beyond 6months is safe in patients with CAT.
YR 2017
FD 2017-07-12
LK http://hdl.handle.net/10668/11419
UL http://hdl.handle.net/10668/11419
LA en
DS RISalud
RD Apr 12, 2025